Clinical trials: Stage II Skin Cancer
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer
This study will evaluate the effect of Avastin (15mg/kg iv) in combination with Docetaxel and Xeloda, given as pre-operative therapy to patients with primary breast cancer.
- Trial name
- NCT02005549
- Testing
- bevacizumab [Avastin], docetaxel, capecitabine [Xeloda]
- Where
- Austria
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Hot Flashes
Hormone Replacement Therapy in Relieving Menopausal Symptoms in Postmenopausal Women With Previous Stage I or Stage II Breast Cancer
RATIONALE: Hormone replacement therapy may be effective in relieving symptoms of menopause, such as hot flashes, night sweats, and vaginal dryness, without causing a recurrence of breast cancer.
- Conditions
- Breast Cancer, Hot Flashes, Menopausal Symptoms, Osteoporosis
- Trial name
- NCT00079248
- Testing
- therapeutic progesterone, conjugated estrogens
- Where
- United Kingdom
- Sponsor
- Institute of Cancer Research, United Kingdom
Melanoma
A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma
The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and dabrafenib therapy regimen in patients with BRAFV600 mutant unresectable and/or metastatic cutaneous melanoma resistant to…
- Trial name
- NCT03391050
- Testing
- APR-246, Dabrafenib
- Where
- 3 sites in Belgium
- Volunteers
- 3 people
- Sponsor
- Aprea Therapeutics
Breast Cancer
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
A Clinical Trial of PM01183 in Metastatic Breast Cancer to assess the antitumor activity of PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts response to PM01183 in Metastatic Breast…
- Trial name
- NCT01525589
- Testing
- PM01183
- Where
- 9 sites in United States, Spain
- Volunteers
- 111 people
- Sponsor
- PharmaMar
Breast Cancer
INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer
This is a phase II, randomized, multi-center, parallel design, window of opportunity trial evaluating intratumoral INT230-6 in up to 90 patients with early stage breast cancer.
- Trial name
- NCT04781725
- Testing
- INT230-6, Saline injection
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
Breast Cancer, Breast Tumors
Re-expression of ER in Triple Negative Breast Cancers
Patients are being asked to take part in this study because they have metastatic breast cancer that is triple negative (does not express estrogen receptor (ER), progesterone receptor (PR) or HER2).
- Conditions
- Breast Cancer, Breast Tumors, Breast Neoplasms
- Trial name
- NCT01194908
- Testing
- Decitabine, LBH589, Tamoxifen
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
This phase II trial studies how well hypofractionated radiation therapy works in treating patients with stage 0-IIB breast cancer.
- Conditions
- Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer, Stage I Breast Cancer
- Trial name
- NOVEMBER (NCT03345420)
- Testing
- Hypofractionated Radiation Therapy
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Utah
Breast Cancer, Cardiac Toxicity
CADY Study ICORG 08-01
RATIONALE: Studying samples of blood in the laboratory from patients with cancer treated with trastuzumab may help doctors learn more about biomarkers related to heart dysfunction.
- Trial name
- NCT00968682
- Testing
- trastuzumab, laboratory biomarker analysis, assessment of therapy complications
- Where
- 14 sites in Ireland
- Volunteers
- 480 people
- Sponsor
- Cancer Trials Ireland
Renal Cell Carcinoma, Melanoma
REduced Frequency ImmuNE Checkpoint Inhibition in Cancers
The REFINE trial aims to asses whether giving an immunotherapy drug less-often to patients with advanced cancer, results in fewer side effects whilst continuing to be an effective treatment.
- Trial name
- REFINE (NCT04913025)
- Testing
- Nivolumab, Pembrolizumab
- Where
- 3 sites in United Kingdom
- Volunteers
- 160 people
- Sponsor
- University College, London
Breast Cancer
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00295893
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)
This is a phase II, multi-center, single-arm, open-label trial to evaluate efficacy of palbociclib with endocrine therapy as adjuvant treatment in women with C-high/G-high risk ER-positive/HER2-negative T1-2N0-1 EBC(Early Breast…
- Trial name
- NCT04247633
- Testing
- Palbociclib
- Where
- South Korea
- Volunteers
- 578 people
- Sponsor
- Samsung Medical Center
Melanoma
A Study of HX008 for the Treatment of Patients With Malignant Melanoma
HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
- Trial name
- NCT04749485
- Testing
- HX008
- Where
- 11 sites in China
- Volunteers
- 119 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Breast Cancer
Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00007904
- Testing
- filgrastim, cyclophosphamide, doxorubicin hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Multi-Media Imagery Program for Breast Cancer Patients (Phase II)
Global Objective: To improve quality of life and reduce stress for breast cancer survivors. To address the late-term and long-term effects of breast cancer treatment, as defined by the Institute of Medicine, including chemo…
- Trial name
- NCT01034215
- Testing
- Envision the Rhythms of Life Program, Envision the Rhythms of Life Program/Distance
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Mind Matters Research LLC
Breast Cancer
Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer
This protocol will evaluate the feasibility and toxicity of dose-dense docetaxel followed by doxorubicin and cyclophosphamide with support given as adjuvant or neoadjuvant treatment of women with node positive and high risk…
- Trial name
- NCT00193115
- Testing
- Docetaxel, Doxorubicin, Cyclophosphamide
- Volunteers
- 32 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)
This is an open label, phase II study evaluating the efficacy and safety of trastuzumab combined with oral chemotherapy (capecitabine or vinorelbine) in patients with HER-2 positive stage I breast cancer.
- Trial name
- NCT04922008
- Testing
- capecitabine and trastuzumab, vinorelbine and trastuzumab
- Volunteers
- 356 people
- Sponsor
- Fudan University
TNBC, Triple Negative Breast Cancer, Brain Metastasases
Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.
This is an open-label, prospective, two-arm, multicenter phase II clinical trial. The aim is to explore the efficacy and safety of radiotherapy combined with cisplatin/carboplatin, adebrelimab, and bevacizumab in patients with…
- Trial name
- ABC-R (NCT07638852)
- Testing
- Radiation Therapy, Adebelimab, Bevacizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Fudan University
HER2-positive Breast Cancer, Breast Adenocarcinoma
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib.
- Conditions
- HER2-positive Breast Cancer, Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7
- Trial name
- NCT03094052
- Testing
- Neratinib, Trastuzumab, Loperamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, San Francisco
Breast Cancer, Cardiac Toxicity
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, fluorouracil, epirubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Conditions
- Breast Cancer, Cardiac Toxicity, Perioperative/Postoperative Complications
- Trial name
- NCT01093235
- Testing
- bevacizumab, cyclophosphamide, docetaxel
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
This phase II trial studies how well giving pazopanib hydrochloride and anastrozole before surgery works in treating patients with stage II-III estrogen receptor-positive breast cancer.
- Conditions
- Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01394211
- Testing
- anastrozole, pazopanib hydrochloride, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Arizona